Top 100 Pharma & Biotech Companies Hiring Medical Science Liaisons in 2025 (Complete Directory)
Field Medical is having a moment. In 2025, brand teams need MSLs who can translate complex data into clinical behavior, defend benefit–risk in tough conversations, and feed evidence gaps back to Medical Affairs. If you’re aiming for an MSL seat this year, build inspection-grade habits with GCP guidelines mastery, document thinking with ALCOA+ rigor, tighten responses using proven test-taking strategies, and rehearse label logic with MSL certification prep. If you’re pivoting from CRC/CRA, compress the learning curve with risk-management playbooks and PI-level leadership cues so KOL meetings feel natural from day one.
What the best MSLs are hired to do in 2025
Turn data into action. Your superpower is a crisp narrative that maps a trial’s design and endpoints to real-world patient journeys. Practice that clarity with exam-style drills, then layer in country-by-country nuance for global launches.
Protect credibility. Everything you say should be traceable. Anchor your responses to GCP documentation discipline and rehearse tough questions using MSL/Medical Monitor Q&A banks so you never wing it.
Close evidence gaps. KOL calls aren’t chit-chat; they’re hypothesis discovery sessions. Capture signals systematically, escalate via project-planning basics, and track actions in a risk register grounded in CAPA thinking.
| Company | Therapeutic Focus (typical MSL coverage) | Common MSL Profiles | |
|---|---|---|---|
| Pfizer | OncologyVaccinesIMID | Oncology PharmD/PhD; vaccine infectious disease MD/MPH. | |
| Novartis | OncologyCardio-renalGene Tx | Heme/solid tumor PhD; cardio PA/NP with trial fluency. | |
| Roche/Genentech | OncologyNeuroOphthalmology | Neuro PhD; retina MD liaison; biomarker-savvy PharmD. | |
| Merck & Co. (MSD) | IOVaccines | IO PhD/MD; vaccine epidemiology MPH/MS. | |
| Johnson & Johnson (Janssen) | OncImmunologyNeuro | Heme PharmD; IMID NP/PA; MS/PD neurology PhD. | |
| Bristol Myers Squibb | OncCardioImmunology | IO PhD; heart failure PharmD; translational immunology PhD. | |
| GSK | VaccinesRespiratory | Infectious disease PharmD; pulmonology NP with trial literacy. | |
| AstraZeneca | OncCVRMRespiratory | Breast/lung PhD; CVRM PharmD; severe asthma NP. | |
| Sanofi | RareVaccinesImmunology | Lysosomal storage PhD; derm/immunology NP/PA. | |
| Amgen | OncBoneCardio | Solid tumor PhD; bone metabolic PharmD; lipid NP. | |
| AbbVie | ImmunologyNeuroAesthetics | Derm/rheum NP; neuro PhD; toxin/aesthetics PharmD. | |
| Eli Lilly | Diabetes/ObesityNeuroOnc | Endo NP/PA; CNS PharmD; breast/lung PhD. | |
| Takeda | GIRareOnc | IBD NP; rare disease PhD; hem/onc PharmD. | |
| Bayer | CardioOnc | Thrombosis PharmD; prostate/renal PhD. | |
| Boehringer Ingelheim | RespiratoryCardio-renalOnc | ILD/IPF NP; CV PharmD; oncology PhD. | |
| Novo Nordisk | DiabetesObesityCardio-renal | Endo NP; metabolic PharmD with outcomes fluency. | |
| Gilead Sciences | VirologyOncInflammation | HIV/viral PharmD; IO PhD; IBD NP. | |
| Regeneron | OncOphthalmologyImmunology | Retina MD liaison; IO PhD; derm PharmD. | |
| Vertex | CFGenetic | Pulmonary NP; genetics PharmD/PhD. | |
| Biogen | NeuroMSALS | Neurology PhD/MD; MS nurse educator pivot. | |
| Seagen | Oncology | Breast/urothelial PhD; ADC literacy. | |
| Genmab | OncHeme | Antibody modalities; heme PharmD. | |
| BMS Cell Therapy (Kite/Juno heritage) | Cell Tx | CAR-T ICU/onc NP; transplant PharmD. | |
| Alexion (AZ Rare Disease) | RareComplement | Hematology PharmD; rare disease RN to MSL. | |
| CSL Behring | HemeImmunology | Bleeding disorders PharmD; immunology NP. | |
| UCB | NeuroImmunology | Epilepsy PhD; derm/rheum NP. | |
| Ipsen | OncRare | NET/endo tumors PhD; rare PharmD. | |
| Astellas | OncUrology | GU PharmD; solid-tumor PhD. | |
| Daiichi Sankyo | OncADC | ADC science PhD; breast/lung PharmD. | |
| Eisai | OncNeuro | HCC/thyroid PharmD; dementia NP. | |
| Otsuka | PsychNephrology | Psych NP/PhD; nephrology PharmD. | |
| Lundbeck | PsychNeuro | Psychiatry PhD; movement disorders NP. | |
| Jazz Pharmaceuticals | SleepOnc | Sleep medicine NP; heme PharmD. | |
| BioMarin | RareGenetic | Metabolic genetics PhD/PharmD. | |
| Sarepta | Gene TxNeuromuscular | DMD specialty NP; gene therapy PhD. | |
| Alnylam | RNAiRare | RNA modalities PhD; cardio-rare NP. | |
| Ionis | ASONeuro | Nucleic-acid PhD; neuromuscular PharmD. | |
| Ultragenyx | RareMetabolic | Peds genetics MD liaison; PharmD rare. | |
| Apellis | ComplementOphthalmology | Retina MD liaison; complement PhD. | |
| argenx | AutoimmuneNeuro | MG neurology NP; immunology PhD. | |
| Exelixis | Onc | GU/GI PhD; TKI literacy. | |
| Incyte | HemeDerm | MPN PharmD; derm immunology NP. | |
| Blueprint Medicines | Precision Onc | Genomics PhD; thoracic PharmD. | |
| Kura Oncology | Heme | Hem-onc PharmD/PhD. | |
| Mirati (BMS) | Onc | KRAS G12C PhD; thoracic PharmD. | |
| Adaptive Biotechnologies | Immuno-sequencing | Precision medicine PhD; heme KOLs. | |
| Immunocore | TCROcular | TCR science PhD; ocular oncology NP. | |
| Nektar Therapeutics | Immunology | Immuno PharmD/PhD. | |
| BeiGene | Onc | Solid/hematologic PhD; global launch fluency. | |
| Zai Lab | Onc | Solid tumors PhD; cross-border field ops. | |
| ACADIA | PsychNeuro | Psycho-geriatrics NP; CNS PharmD. | |
| Corcept | Endocrine | Endocrinology NP/PA; metabolic PharmD. | |
| Insmed | PulmonaryRare | Nontuberculous mycobacteria NP; rare disease PharmD. | |
| Cytokinetics | CardioMuscle | HF PharmD; neuromuscular PhD. | |
| BridgeBio | GeneticCardio | Inherited cardio NP; genetics PhD. | |
| Biohaven | NeuroMigraine | Migraine NP; CNS PharmD. | |
| Horizon (Amgen) | ImmunologyRare | Rheum NP; rare PharmD. | |
| Organon | Women’s Health | OB/GYN NP/PA; endocrine PharmD. | |
| Karuna (BMS) | Psych | Schizophrenia NP; CNS PhD. | |
| Revance | AestheticsTherapeutic toxin | Neurotoxins PharmD; neuro NP. | |
| Apellis (Ophth) | Retina | Retina MD liaison; PharmD. | |
| GenSight Biologics | Gene TxOphth | Inherited retinal disease PhD. | |
| Santen | Ophthalmology | Glaucoma/cornea PharmD/OD. | |
| Ferring | GIFertility | IBD NP; reproductive health PharmD. | |
| Galderma | Derm | Derm NP; aesthetic injectables PharmD. | |
| Leo Pharma | Derm | Psoriasis/AD NP; derm PharmD. | |
| Moderna | VaccinesRespiratory | ID PharmD; vaccinology PhD. | |
| BioNTech | IOVaccines | IO PhD; translational immunology PharmD. | |
| Valneva | Vaccines | Tropical ID NP; PH epidemiology. | |
| Novavax | Vaccines | Respiratory ID PharmD/MPH. | |
| Sangamo | Gene Editing | Genetics PhD; peds rare NP. | |
| Bluebird bio | Gene TxHeme | Transplant PharmD; pedi heme NP. | |
| Sana Biotechnology | Cell/Gene | Cell therapy PhD; CGT MSL. | |
| CRISPR Therapeutics | Gene Editing | Genomics PhD; heme PharmD. | |
| Editas Medicine | Gene Editing | Ocular/rare PhD; genetics PharmD. | |
| Vertex Cell & Genetic Tx | Genetic | Translational genetics PhD. | |
| PTC Therapeutics | Rare | Neuromuscular PharmD; peds NP. | |
| Sobi | RareHeme | Bleeding disorders PharmD; rare NP. | |
| Akebia | Nephrology | Renal PharmD; CKD NP. | |
| Travere | Rare renal | Nephrology NP; rare PharmD. | |
| Alkermes | PsychAddiction | Psych NP; outcomes PharmD. | |
| Amarin | Cardio-metabolic | Lipid NP/PA; outcomes PharmD. | |
| Apellis (Immunology) | Complement | Immunology PhD; retina MD liaison. | |
| Genentech (Neuro) | MSALS | Neuro PhD; MS NP. | |
| Aimmune (Nestlé Health Science) | Allergy | Allergy/immunology NP; peds PharmD. | |
| Grifols | PlasmaImmunology | Immunology PharmD; hematology NP. | |
| CSL Vifor | RenalIron | CKD PharmD; anemia NP. | |
| Mallinckrodt (Specialty) | HCP-driven specialty | Hosp PharmD; critical care NP. | |
| Kyowa Kirin | RareOnc | Rare PharmD; solid-tumor PhD. | |
| Travere (repeat? use other) → Replace with | Ascendis Pharma | EndocrineRare | Endo NP; growth disorders PharmD. |
| Exscientia (Translational) | Onc | Translational PhD; precision MSL. | |
| Exact Sciences (Oncology Dx) | Onc-Dx | MSL/MA for diagnostics; GI oncology PharmD. | |
| Guardant Health (Theranostics) | Onc-Dx | Liquid biopsy PhD; thoracic PharmD. | |
| Natera (Signatera) | MRD | MRD genomics PhD; heme PharmD. | |
| Clovis Oncology (legacy markets) | Onc | Ovarian PharmD; PARP literacy. | |
| MacroGenics | IO | Immuno-oncology PhD. | |
| Karyopharm | Heme | MM PharmD; heme PhD. | |
| TG Therapeutics | Heme | CLL PharmD; heme NP. | |
| EUSA Pharma | Onc | Solid-tumor PharmD. | |
| Seagen (Breast/Urothelial) | ADC | ADC science PhD/PharmD. | |
| Acrivon | Precision Onc | Genomics PhD; thoracic PharmD. | |
| Denali Therapeutics | Neuro | Neurodegeneration PhD; movement NP. | |
| FibroGen | Fibrosis | Pulmonary PharmD; renal NP. | |
| Gossamer Bio | ImmunologyPulmonary | Pulm PharmD; immunology PhD. | |
| Halozyme | OncDrug delivery | Onc PharmD; biologics device NP. | |
| Ionis (Cardio/Neuro divisions) | ASO | RNA PharmD/PhD; cardio CNS splits. | |
| Loxo (Lilly Oncology) | Precision Onc | Pathway biology PhD; thoracic PharmD. | |
| Merck KGaA / EMD Serono | OncNeuro | IO PhD; MS PharmD. | |
| Roivant | ImmunologyCNS | Platform MSL; cross-asset PhD. | |
| Ultragenyx (Gene Tx) | Rare | Genetics PhD; peds NP. |
How to use this directory (and get interviews fast)
Bucket your targets by therapeutic story. Recruiters scan for disease-area fluency first. If you’ve been a CRC in GI or oncology, you’re already halfway to compelling. Cement that by reading PI responsibilities and protocol development guides so your answers cut through.
Ship proof, not promises. Bring a two-page KOL brief, a mock slide with endpoint interpretation, and a benefit–risk memo. Keep language clean using study tips from certified experts; for global roles, layer in country trend insight and Brexit impacts to show market awareness.
Which therapeutic area should we build your MSL portfolio for first?
30–60–90 MSL job-winning plan (optimized for 2025 launches)
Days 1–30 — Build the inspection-ready core.
Craft a one-page therapeutic narrative (trial design → endpoint → patient behavior) and a benefit–risk memo. Ground every line in GCP documentation standards. For interviews, rehearse with MSL exam banks and stabilize mindset using exam-anxiety tools.
Days 31–60 — Prove KOL-readiness.
Write two KOL call briefs, one data visualization slide, and a Q&A appendix. Use project planning techniques to track follow-ups and pushbacks. Add a salary target sheet based on 2025 compensation data so you negotiate with confidence.
Days 61–90 — Operate like Field Medical already.
Run weekly evidence gap sprints with mock brand partners; convert findings into medical initiatives. Align your actions to risk management so you speak commercialization and compliance. Keep your study environment tight with focus-friendly setups to maintain pace.
Offer-winning artifacts you can assemble this weekend
Therapeutic one-pager with timeline, pivotal endpoints, and objection-handling scripts (anchor language to test-taking clarity).
Two KOL briefs that translate publication claims into clinic-day changes (file them with ALCOA+ evidence).
Field prompt library for payer, nurse educator, and investigator audiences (review with PI leadership cues).
Region memo showing how Brexit dynamics or India’s trial expansion shape access and adoption.
FAQs
-
Many teams prefer PharmD/PhD/MD, but strong NP/PA/RN applicants win when they bring disease-area credibility, a portfolio of artifacts, and GCP-grade documentation. Use MSL exam prep to signal commitment.
-
They anticipate objections and translate biomarker subtleties into clinic decisions. That clarity comes from relentless practice with question banks and precise risk-management framing during tough calls.
-
Repackage your monitoring wins into evidence stewardship stories. Build a KOL call debrief template and demonstrate inspection-calm using ALCOA+ methods. If you need structure, lean on MSL exam study guides.
-
Not the good ones. AI drafts and organizes, but credibility lives in clinical judgment and relationship depth. Treat AI like a co-pilot, then present human-owned decisions using crisp language honed with test-taking strategies and documentation discipline.
-
Use market bands from 2025 salary intel and tune by therapy (oncology and rare often lead). Add travel load and after-hours advisory boards to your calculus; then negotiate with a value narrative grounded in KPI impact (publications, trials supported, KOL coverage).
